These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18644198

  • 1. High-throughput screening technologies for drug glucuronidation profiling.
    Trubetskoy O, Finel M, Trubetskoy V.
    J Pharm Pharmacol; 2008 Aug; 60(8):1061-7. PubMed ID: 18644198
    [Abstract] [Full Text] [Related]

  • 2. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.
    Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S.
    Chem Res Toxicol; 2006 May; 19(5):701-9. PubMed ID: 16696573
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.
    Court MH.
    Methods Enzymol; 2005 May; 400():104-16. PubMed ID: 16399346
    [Abstract] [Full Text] [Related]

  • 6. High throughput screening assay for UDP-glucuronosyltransferase 1A1 glucuronidation profiling.
    Trubetskoy OV, Finel M, Kurkela M, Fitzgerald M, Peters NR, Hoffman FM, Trubetskoy VS.
    Assay Drug Dev Technol; 2007 Jun; 5(3):343-54. PubMed ID: 17638534
    [Abstract] [Full Text] [Related]

  • 7. Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone.
    Nishiyama T, Kobori T, Arai K, Ogura K, Ohnuma T, Ishii K, Hayashi K, Hiratsuka A.
    Arch Biochem Biophys; 2006 Oct 01; 454(1):72-9. PubMed ID: 16949544
    [Abstract] [Full Text] [Related]

  • 8. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
    Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE.
    Drug Metab Dispos; 2004 Nov 01; 32(11):1201-8. PubMed ID: 15304429
    [Abstract] [Full Text] [Related]

  • 9. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes.
    Mano Y, Usui T, Kamimura H.
    Drug Metab Dispos; 2007 Apr 01; 35(4):602-6. PubMed ID: 17267620
    [Abstract] [Full Text] [Related]

  • 10. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
    Guillemette C.
    Pharmacogenomics J; 2003 Apr 01; 3(3):136-58. PubMed ID: 12815363
    [Abstract] [Full Text] [Related]

  • 11. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO, Knights KM, Houston JB, Mackenzie PI.
    Biochem Pharmacol; 2006 May 28; 71(11):1531-9. PubMed ID: 16455060
    [Abstract] [Full Text] [Related]

  • 12. Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6.
    Soikkeli A, Kurkela M, Hirvonen J, Yliperttula M, Finel M.
    Assay Drug Dev Technol; 2011 Oct 28; 9(5):496-502. PubMed ID: 21438674
    [Abstract] [Full Text] [Related]

  • 13. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
    Nagar S, Remmel RP.
    Oncogene; 2006 Mar 13; 25(11):1659-72. PubMed ID: 16550166
    [Abstract] [Full Text] [Related]

  • 14. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.
    Hanioka N, Naito T, Narimatsu S.
    Chemosphere; 2008 Dec 13; 74(1):33-6. PubMed ID: 18990428
    [Abstract] [Full Text] [Related]

  • 15. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
    Soulard P, McLaughlin M, Stevens J, Connolly B, Coli R, Wang L, Moore J, Kuo MS, LaMarr WA, Ozbal CC, Bhat BG.
    Anal Chim Acta; 2008 Oct 03; 627(1):105-11. PubMed ID: 18790133
    [Abstract] [Full Text] [Related]

  • 16. Substrate specificity of human hepatic udp-glucuronosyltransferases.
    Burchell B, Lockley DJ, Staines A, Uesawa Y, Coughtrie MW.
    Methods Enzymol; 2005 Oct 03; 400():46-57. PubMed ID: 16399342
    [Abstract] [Full Text] [Related]

  • 17. Glucuronidation and the UDP-glucuronosyltransferases in health and disease.
    Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, Ritter JK.
    Drug Metab Dispos; 2004 Mar 03; 32(3):281-90. PubMed ID: 14977861
    [Abstract] [Full Text] [Related]

  • 18. UDP-glucuronosyltransferases and clinical drug-drug interactions.
    Kiang TK, Ensom MH, Chang TK.
    Pharmacol Ther; 2005 Apr 03; 106(1):97-132. PubMed ID: 15781124
    [Abstract] [Full Text] [Related]

  • 19. Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.
    Kaivosaari S, Toivonen P, Aitio O, Sipilä J, Koskinen M, Salonen JS, Finel M.
    Drug Metab Dispos; 2008 Aug 03; 36(8):1529-37. PubMed ID: 18474681
    [Abstract] [Full Text] [Related]

  • 20. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.
    Sorich MJ, Miners JO, McKinnon RA, Smith PA.
    Mol Pharmacol; 2004 Feb 03; 65(2):301-8. PubMed ID: 14742671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.